R & D Pipeline

program

target

indication

moa

development stage

CT3001
TMER1-i
Small molecule

GPR35
a.k.a.
Kynurenic Acid Receptor

IO, first-in-class
GPR35+ IDO1+ Tumors:
Colon, Pdac, Gastric, NSCLC

Hippo-YAP regulator
Block IDO-mediated tumor immune escape
Block tumor growth

CT3001 Phase 1/2a(Click to See Clinical Trial Details)

CT3021
TMER2-i
Small molecule

Adenosine Receptors
A2a, A2b, A1

IO, Best-in-class
A1+ CD73+ Tumors

Highly potent triple antagonist
(Ki = 0.37 nM [A2a], 1.76 nM [A2b], 1.26 nM [A1]
Full antagonism in high adenosine TME

CT3021 IND-Enabling(Click to See Details)

TMER3-i
Small molecule

Undisclosed

IO, first-in-class
Solid Tumors

Hippo-YAP regulator
Block tumor immune escape
Block tumor growth

Candidate Nomination

TMER4-i
Small molecule

Undisclosed

IO, first-in-class
Solid Tumors

Hippo-YAP regulator
Block tumor growth

“Hit” to “Lead”

PD1/PD-L1 Blocker
Small molecule

IO
mono/combo with other TMER-i

“Hit” to “Lead”